EUCTR2008-006373-33-IT进行中（未招募）不适用
Effect of montelukast on levels of metalloproteinase-9 (MMP-9), MMP-12, tissue inhibitor metalloproteinase-1 (TIMP-1), procollagen peptide type 1 C-terminal (PICP) and TGF-beta1 on induced sputum of children suffering from intermittent asthma. - ND
AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA0 个研究点开始时间: 2008年12月30日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Atopic children (6-14 years) with mild intermittent asthma
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Assumption of ICS in previous 3 months; acute exacerbations of bronchial asthma; pulmonar diseases other than asthma, high- or low-respiratory tract infection in previous 3 weeks.
研究者
相似试验
已完成
4 期
Montelukast effect in patients with chronic obstructive pulmonary diseaseChronic Obstructive Pulmonary Disease.Other chronic obstructive pulmonary diseaseIRCT20190423043361N1Khoram-Abad University of Medical Sciences74
已完成
2 期
Sputum Matrix Metalloproteinases (MMP) mRNA and MontelukastAsthmaNCT00947453University of East Anglia15
招募中
3 期
The effect of Montelukast on COVID 19 disease activityIRCT20181208041886N3Abidi Pharmaceutical company60
已完成
不适用
Clinical evaluation of matrix metalloproteinases as early diagnostic markers of peritoneal deterioration and encapsulating peritoneal sclerosis.encapsulating peritoneal sclerosis (EPS)/ sclerosing encapsulating peritonitis(SEP)JPRN-UMIN000010572Division of Nephrology, Department of Medicine, Jichi Medical University400
已完成
3 期
Evaluation of montelukast efficacy on clinical and FEV1/PEFR improvement in acute basthma attackAcute attack asthma.AsthmaIRCT2015092215446N5Vice chanceller for research, Ahvaz Jundishapur University of Medical Sciences80